Lung Cancer

Cough in Lung Cancer Associated With Gastrointestinal Symptoms

Cough in Lung Cancer Associated With Gastrointestinal Symptoms

By

The median duration of reported cough at study entry was 52 weeks and it was severe enough in more than half of participants that it warranted treatment.

Thoracotomy, Adjuvant Therapy Increase Risk for Opioid Use After Lung Resection

Thoracotomy, Adjuvant Therapy Increase Risk for Opioid Use After Lung Resection

By

Being 64 years or younger, being male, having underwent a thoracotomy, and using adjuvant therapy were all associated with a greater risk for persistent opioid use.

After NSCLC Resection, No Benefit to More Frequent Surveillance

After NSCLC Resection, No Benefit to More Frequent Surveillance

More frequent postsurgical surveillance is not associated with improved survival in non-small cell lung cancer.

Lung Cancer Mortality Predicted to Drop by 79%

Lung Cancer Mortality Predicted to Drop by 79%

Annual number of deaths from lung cancer are expected to continue to decrease despite the growth and aging of the US population.

Lorlatinib Approved for Previously-Treated ALK-Positive Metastatic NSCLC

Lorlatinib Approved for Previously-Treated ALK-Positive Metastatic NSCLC

By

The FDA has approved Lorbrena (lorlatinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC.

Pembrolizumab Combination Approved for First-Line Metastatic Squamous NSCLC Treatment

Pembrolizumab Combination Approved for First-Line Metastatic Squamous NSCLC Treatment

By

The FDA has approved Keytruda in combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of patients with metastatic squamous NSCLC.

Durvalumab Extends Survival in Stage 3 Non-Small Cell Lung Cancer

Durvalumab Extends Survival in Stage 3 Non-Small Cell Lung Cancer

Both overall and progression-free survival were longer with durvalumab vs placebo.

Commonly Prescribed Antihypertensives Linked to Increased Lung Cancer Risk

Commonly Prescribed Antihypertensives Linked to Increased Lung Cancer Risk

By

To investigate the association between this commonly used antihypertensive class and lung cancer, researchers conducted a population based cohort study involving 992,061 patients from the United Kingdom Clinical Practice Research Datalink.

Open Surgery for Early Lung Cancer Tied to Long-Term Opioid Use

Open Surgery for Early Lung Cancer Tied to Long-Term Opioid Use

Patients who had video-assisted thoracoscopic surgery were less likely to use opioids long term.

Tobacco Use Remains Leading Modifiable Cause of Cancer

Tobacco Use Remains Leading Modifiable Cause of Cancer

Tobacco control could prevent more cancer deaths than any other strategy.

Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer

Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer

By

Significant improvements were seen with the addition of atezolizumab to CnP in stage IV non-squamous non-small cell lung cancer, regardless of patient PD-L1 status.

Metastatic NSCLC Treatment Aided by Plasma-Based Genotyping

Metastatic NSCLC Treatment Aided by Plasma-Based Genotyping

Most patients with metastatic non-small cell lung cancer who received targeted therapy based on plasma result achieved clinical response.

Lung Cancer Deaths 28% Lower in California Than Rest of US

Lung Cancer Deaths 28% Lower in California Than Rest of US

In individuals aged 18 to 35, California has had larger drops in smoking initiation, intensity, and higher rates of quitting.

Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC

Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC

By

Researchers investigated whether the rates of immune-related adverse events linked to treatment with nivolumab or pembrolizumab were similar across 2 different cancer types.

Longer Survival in NSCLC With Brigatinib vs Crizotinib

Longer Survival in NSCLC With Brigatinib vs Crizotinib

Longer progression-free survival was significantly longer in patients with ALK-positive disease who did not previously take an ALK inhibitor.

Integrated Classifier Identifies Benign Lung Nodules

Integrated Classifier Identifies Benign Lung Nodules

Classifier integrates relative abundance of 2 plasma proteins with clinical risk prediction model for lung nodules.

Vizimpro Approved as First-Line Treatment for EGFR-Mutated Metastatic NSCLC

Vizimpro Approved as First-Line Treatment for EGFR-Mutated Metastatic NSCLC

By

The approval was based on data from the ARCHER 1050 open-label, active controlled study which randomized patients with unresectable, metastatic NSCLC to treatment with either dacomitinib (N=227) or gefitinib (N=225).

Salvage Therapy for Recurrent SABR-Treated Early-Stage NSCLC Increases Survival

Salvage Therapy for Recurrent SABR-Treated Early-Stage NSCLC Increases Survival

By

Salvage treatment for recurrence of early-stage non-small cell lung cancer after initial treatment with stereotactic ablative radiotherapy improved patient survival.

RET Inhibitor Gets Breakthrough Tx Status for NSCLC, Medullary Thyroid Cancer

RET Inhibitor Gets Breakthrough Tx Status for NSCLC, Medullary Thyroid Cancer

By

LOXO-292 is being evaluated in the ongoing Phase 1/2 LIBRETTO-001 clinical trial.

Poor, Non-English Speaking Cancer Patients Need Support

Poor, Non-English Speaking Cancer Patients Need Support

Serving patients' specific needs, such as referral to socioeconomic support, can improve care.

High-Quality Diet Linked to Lower Mortality in Cancer Survivors

High-Quality Diet Linked to Lower Mortality in Cancer Survivors

High-quality diet linked to reduced risk of overall and cancer-specific mortality vs poor-quality diet.

Poor Shared Decision Making for Lung Cancer Screening

Poor Shared Decision Making for Lung Cancer Screening

Physicians universally recommended lung cancer screening and rarely discuss harms.

Early CT Detection of Small Cell Lung Cancer Does Not Improve Survival Rates

Early CT Detection of Small Cell Lung Cancer Does Not Improve Survival Rates

By

Screening for small cell lung cancer using low-dose computed tomography had no effect on outcomes for patients.

Lung Cancer Imaging in Asymptomatic Patients: To Screen or Not to Screen?

Lung Cancer Imaging in Asymptomatic Patients: To Screen or Not to Screen?

By

Although screening for lung cancer with low-dose computed tomography has demonstrated a reduction in mortality, some experts say the benefits do not outweigh the potential harms.

Racial Disparities in Surgical Treatment of Lung Cancer

Racial Disparities in Surgical Treatment of Lung Cancer

By

As lung cancer screening disseminates into clinical practice, efforts designed to target black men should be prioritized.

Keytruda With Pemetrexed + Platinum Chemotherapy OK'd for Nonsquamous NSCLC

Keytruda With Pemetrexed + Platinum Chemotherapy OK'd for Nonsquamous NSCLC

By

The median OS was not reached at the time of the data cut-off in the pembrolizumab plus chemotherapy arm and was 11.3 months for those in the chemotherapy arm.

Opdivo Approved to Treat Metastatic Small Cell Lung Cancer

Opdivo Approved to Treat Metastatic Small Cell Lung Cancer

By

Data showed that 12% responded to treatment based on assessment by a Blinded Independent Central Review, regardless of PD-L1 expression; 11% had a partial response, and 1 patient had a complete response (0.9%).

Broad Genetic Testing for NSCLC May Not Improve Survival

Broad Genetic Testing for NSCLC May Not Improve Survival

Compared with routine genetic testing, there was no improvement in unadjusted mortality rate in non-small cell lung cancer.

Disparities Remain in Prevalence of Cancer Screening Tests

Disparities Remain in Prevalence of Cancer Screening Tests

From 2000 to 2015, individuals without insurance or usual care were less likely to have undergone cancer screening.

Biomarker Panel May Improve Lung Cancer Risk Assessment

Biomarker Panel May Improve Lung Cancer Risk Assessment

Risk score based on panel of four circulating protein biomarkers.

Sign Up for Free e-newsletters